Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Enrasentan. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EDNRA known ✓ | P25101 | 20/20 | 1.00 |
| ▸ | EDNRB known ✓ | P24530 | 19/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Enrasentan SCHEMBL29356829 | 1.00 | EDNRA (1.00) | EDNRAEDNRB | |
| Enrasentan SCHEMBL7636324 | 1.00 | EDNRA (1.00) | EDNRAEDNRB | |
| Enrasentan SCHEMBL8206689 | 1.00 | EDNRA (1.00) | EDNRAEDNRB | |
| Enrasentan SCHEMBL1031130 | 1.00 | EDNRA (1.00) | EDNRAEDNRB | |
| Enrasentan SCHEMBL8008492 | 0.98 | EDNRA (0.97) | EDNRAEDNRB | |
| Enrasentan SCHEMBL7660593 | 0.98 | EDNRA (0.95) | EDNRAEDNRB | |
| Enrasentan SCHEMBL7610103 | 0.98 | EDNRA (0.95) | EDNRAEDNRB | |
| SCHEMBL13038489 | 0.97 | EDNRA (0.93) | EDNRAEDNRB | |
| SCHEMBL8203979 | 0.97 | EDNRA (0.93) | EDNRAEDNRB | |
| SCHEMBL7538909 | 0.96 | EDNRA (0.92) | EDNRAEDNRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 51 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100040666-A1 | Method for Control of Drug Elution Rate and Composition for Coating of Drug-Eluting Stent | TOKYO MEDICAL AND DENTAL UNIVERSITY (JP) | 2010-02-18 | — | — | US | claimed |
| EP-1894582-A1 | METHOD FOR CONTROL OF DRUG ELUTION RATE AND COMPOSITION FOR COATING OF DRUG-ELUTING STENT | Tokyo Medical and Dental University (JP) | 2008-03-05 | — | — | EP | claimed |
| US-20020002177-A1 | Endothelin receptor antagonists | SMITHKLINE BEECHAM CORPORATION | 2002-01-03 | — | — | US | claimed |
| US-8980874-B2 | Method and composition for treating diabetic ketoacidosis | MIDWESTERN UNIVERSITY (US) | 2015-03-17 | — | — | US | disclosed |
| US-20130225531-A1 | METHOD AND COMPOSITION FOR TREATING ALZHEIMER'S DISEASE AND DEMENTIAS OF VASCULAR ORIGIN | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2013-08-29 | — | — | US | disclosed |
| US-8410148-B2 | Method and composition for potentiating an opiate analgesic | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2013-04-02 | — | — | US | disclosed |
| US-20120083447-A1 | Novel Therapeutic Treatments Using Centhaquin | MIDWESTERN UNIVERSITY (US) | 2012-04-05 | — | — | US | disclosed |
| US-20120070513-A1 | Method and Composition for Treating Diabetic Ketoacidosis | GULATI ANIL (US) | 2012-03-22 | — | — | US | disclosed |
| US-7976835-B2 | Methods and compositions for preventing and treating solid tumors | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2011-07-12 | — | — | US | disclosed |
| US-7927613-B2 | Pharmaceutical co-crystal compositions | UNIVERSITY OF SOUTH FLORIDA (US) | 2011-04-19 | — | — | US | disclosed |
| US-20100311665-A1 | Method and Composition for Potentiating an Opiate Analgesic | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2010-12-09 | — | — | US | disclosed |
| US-6143907-A | 3-phenyl-1-methylenedioxyphenyl-indane-2-carboxylic acid derivatives | SMITHKLINE BEECHAM CORPORATION (US) | 2000-11-07 | — | — | US | disclosed |
| US-6087389-A | TREATING CARDIOVASCULAR AND RENAL DISEASES INCLUDING HYPERTENSION, ACUTE AND CHRONIC RENAL FAILURE, CYCLOSPORINE INDUCED NEPHROTOXICITY, STROKE, CEREBROVASCULAR VASOSPASM, MYOCARDIAL ISCHEMIA, ANGINA, HEART FAILURE, ATHEROSCLEROSIS | SMITHKLINE BEECHAM CORPORATION (US) | 2000-07-11 | — | — | US | disclosed |
| US-6080862-A | PREPARING (1S, 2R, 3S)-3-(2-HYDROXYETH-1-YLOXY)-4-METHOXYPHENYL) 1-(3,4-METHYLENEDIOXYPHENYL) 5-(PROP-1-YLOXY)INDANE-2-CARBOXYLIC ACID | SMITHKLINE BEECHAM CORPORATION (US) | 2000-06-27 | — | — | US | disclosed |
| EP-0924207-A1 | CHROMENE-3-CARBOXYLATE DERIVATIVES | SHIONOGI & CO., LTD. (JP) | 1999-06-23 | — | — | EP | disclosed |
| EP-0915699-A1 | STEREOSELECTIVE SYNTHESIS OF ENDOTHELIN RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 1999-05-19 | — | — | EP | disclosed |
| CN-1206415-A | Process for preparing 3-phenyl-1-methylenedioxyphenyl-1, 2-indane-2-carboxylic acid derivatives | SMITHKLINE BEECHAM CORP (US) | 1999-01-27 | — | — | CN | disclosed |
| EP-0876352-A1 | PROCESS | SMITHKLINE BEECHAM CORPORATION (US) | 1998-11-11 | — | — | EP | disclosed |
| WO-1997017071-A1 | STEREOSELECTIVE SYNTHESIS OF ENDOTHELIN RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 1997-05-15 | — | — | WO | disclosed |
| WO-1997017330-A1 | PROCESS | SMITHKLINE BEECHAM CORPORATION (US) | 1997-05-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120083447-A1 | Novel Therapeutic Treatments Using Centhaquin | ADRB3, ADRA2A, ADRB2 | EDNRA 141/4885EDNRB 148/4885 |
| US-20120070513-A1 | Method and Composition for Treating Diabetic Ketoacidosis | EDNRB, EGLN3, BDKRB2 | EDNRA 4/4885EDNRB 1/4885 |
| US-20100040666-A1 | Method for Control of Drug Elution Rate and Composition for Coating of Drug-Eluting Stent | EDNRB, EDNRA, EPHB2 | EDNRA 2/4885EDNRB 1/4885 |
| US-20130225531-A1 | METHOD AND COMPOSITION FOR TREATING ALZHEIMER'S DISEASE AND DEMENTIAS OF VASCULAR ORIGIN | PSEN1, PSEN2, CHAT | EDNRA 11/4885EDNRB 7/4885 |
| US-20020002177-A1 | Endothelin receptor antagonists | EDNRA, EDNRB, ECE1 | EDNRA 1/4885EDNRB 2/4885 |
| US-20100311665-A1 | Method and Composition for Potentiating an Opiate Analgesic | OPRK1, OPRL1, OPRM1 | EDNRA 6/4885EDNRB 8/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.